【摘要】 目的 評價葛根素注射液（PI）聯合低分子肝素（LMWH）治療不穩定型心絞痛（UAP）的療效和安全性。 方法 計算機檢索中國生物醫學文獻數據庫（CBM）、中國期刊全文數據庫（CNKI）、中文科技期刊全文數據庫（VIP-維普）、萬方-數字化期刊全文庫，納入在常規治療上加用PI和LMWH對比單純常規治療的隨機對照試驗（RCT），對納入研究進行質量評價和Meta分析。 結果 共納入21個RCT，均為C級文獻。Meta分析結果顯示，在臨床癥狀療效顯效率、心電圖療效顯效率和有效率指標方面，兩組差異有統計學意義:RR（95%CI）分別為:1.63（1.48，1.79）、1.57（1.34，1.83）及1.28（1.10，1.49）。 結論 基于上述證據，在常規治療UAP上加用PI和LMWH療效優于常規治療。【Abstract】 Objective To evaluate the effect of the puerarin injection (PI) combined with low molecular weight heparins (LMWH) on unstable angina pectoris (UAP). Methods Randomized controlled trials (RCT) of PI combined with LMWH treating UAP were gathered from CBM, CNKI, VIP, and Wanfang data bases; and study quality was evaluated and the Meta-analysis was carried out. Results A total of 21 RCT were identified, of which all were in graded C. According to Meta-analysis, the differences of the clinic excellent rate, electrocardiogram excellent rate and effective rate between the two groups were significant; the RR (95%CI) were: 1.63 (1.48, 1.79), 1.57 (1.34, 1.83), and 1.28 (1.10, 1.49). Conclusion Based on the evidence recently, PI and LMWH adding is better than ordinary treatment for UAP.
【摘要】 目的 研究天麻素注射液治療椎-基底動脈供血不足（vertebrobasilar insufficiency，VBI）的療效和安全性。 方法 檢索CBM、CNKI、VIP、萬方數據庫，檢索時間為各數據庫建庫至2010年5月，納入天麻素注射液對比其他藥物治療VBI的隨機對照試驗（RCT），對納入研究進行方法學質量評價后，采用RevMan 5.0軟件進行Meta分析。 結果 納入8個RCT，涉及受試者648例，均為C級文獻，Meta分析結果顯示:天麻素注射液對比丹參注射液治療VBI，顯效率和總有效率差異均有統計學意義[RR=1.63，95%CI （1.37，1.95）和RR=1.21，95%CI （1.12，1.30）]。 結論 基于當前證據，臨床治療VBI，天麻素注射液療效優于丹參注射液，且安全性較好。【Abstract】 Objective To study the effectiveness and safety of gastrodine injection for vertebrobasilar insufficiency (VBI). Methods Databases of CBM, CNKI, VIP and Wanfang were searched from the time of the establishment till May 2010 and randomized controlled trials (RCT) of gastrodine injection compared with other positive drugs for VBI were included. Quality evaluation and meta-analysis by using RevMan 5.0 were performed. Results A total of 8 grade-C RCTs including 648 cases were gathered. The results of meta-analysis showed that the difference of excellent and effective rates between danshen injection and gastrodine injection for VBI were significant: RR=1.63, 95%CI (1.37, 1.95) and RR=1.21, 95%CI (1.12, 1.30). Conclusion Based on current evidence, compared with danshen injection, gastrodine injection is better and safer for VBI.
Objective To compare clinical outcome of bioabsorbable interference screws (BS) with metal Interference screws (MS) for restruction of anterior cruciate ligament (ACL). Methods The electronic databases (PubMed, EMbase, Cochrane Central Register of Controlled Trials, CBM, CNKI, and VIP) were searched in order to retrieve randomized controlled trials (RCTs) about comparing BS with MS for restruction of ACL. In addition, reference lists from original studies and review articles were handsearched. The Jadad’s scale and Cochrane collaboration’s RevMan 5.0 software were used for assessing trial methodological quality and data analyses. Results Eleven RCTs were included. There were 935 participants that met inclusion criteria in all studies. Results of Meta-analyses showed the MS group had a higher Lysholm score. However, no significant differences were found in Lanchman Test, IKDC Data and KT1000 result between patients treated by BS and by MS. Conclusion Bioabsorbable interference screws provide equivalent clinical outcomescompared with metal interference screws. However, further confirmation is required because of varieties of types and complex compositions.
Objective To systematically analyze the randomized controlled trials that compare tissue-engineered skin (TES) with conventional treatment for chronic diabetic foot ulcer (DFU) in terms of effectiveness and utilization.Methods We searched the electronic databases (PubMed, Embase, Cochrane Central Register of Controlled Trials, CBMWeb, CNKI, and VIP) in order to compare the efficiency and safety between TES and conventional treatment (CT) in the patients with DFU. In addition, we manually searched reference lists from original studies and review articles.Results Seven trials were included, which were all randomized controlled trials and had a duration of DFU over 6 weeks. There were 880 participants that met inclusion criteria in all studies, and all patients underwent pre-treatment procedures and were treated by TES (human skin equivalents, living skin equivalents or bioengineered skin, such as Graftskin, Dermagraft and Graftjacket) for 12 weeks. All trials had two groups: the treatment group and the control group, but the two trials divided the treatment groups into 3 different dosages and 2 different ulcer allocation subgroups, respectively. Meta-analysis results showed significant differences in the rate of complete wound closure (Plt;0.0001, 95%CI 0.08 to 0.20) and in the occurrence of complications and severe adverse events (P=0.008, 95%CI – 0.06 to – 0.01) between TES treated patients and conventionally treated patients. Conclusion The review shows TES improves completed closure of DFU compared with CT, and it is more effective in reducing side effects.